Last $68.46 USD
Change Today +0.40 / 0.59%
Volume 536.0K
ALNY On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 08/28/14 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

John K. Clarke

Founder, Chairman, Chairman of Nominating & Corporate Governance Committee and Member of Audit Committee, Alnylam Pharmaceuticals, Inc.
AgeTotal Calculated CompensationThis person is connected to 113 board members in 5 different organizations across 7 different industries.

See Board Relationships
60$287,823

Background*

Mr. John K. Clarke co-founded Cardinal Partners in 1997 and has been its Managing General Partner since October 1997. Mr. Clarke spent two decades in venture capital industry, which he entered in 1982. Mr. Clarke served as General Partner at DSV. During his tenure there, he led its health care and life sciences efforts and co-founded and served as an Interim Chief Executive Officer of a number of companies including Alkermes, Arris Pharmaceuticals, the DNX Corporation, ...

Read Full Background

Corporate Headquarters*

300 Third Street
Cambridge, Massachusetts 02142

United States

Phone: 617-551-8200
Fax: 617-551-8101

Board Members Memberships*

Director
Director
Director
1987-2003
Former Director
1992-2005
Former Director, Member of Audit Committee and Member of Compensation Committee
1998-N/A
Director, Chairman of Compensation Committee and Member of Nominating & Corporate Governance Committee
2002-Present
Founder, Chairman, Chairman of Nominating & Corporate Governance Committee and Member of Audit Committee
2002-Present
Independent Director, Chairman of Compensation Committee and Member of Audit Committee
2004-N/A
Director and Member of Audit Committee
2010-Present
Director and Member of Audit Committee

Education*

MBA
University of Pennsylvania - The Wharton School
BA
Harvard College

Other Affiliations*

Annual Compensation*

There is no Annual Compensation data available.

Stock Options*

There is no Stock Options data available.

Total Compensation*

Total Annual Cash Compensation$60,000
Total Calculated Compensation$287,823
*Data is at least as current as the most recent Definitive Proxy.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ALNY:US $68.46 USD +0.40

COMPETITOR COMPENSATION

NamePosition/
Company
Compensation
Ali Mortazavi Chief Executive and Director
Silence Therapeutics plc
70.0K GBP
Hans G. C. P. Schikan Chief Executive Officer and Member of Management Board
Prosensa Holding N.V.
--
Mark W. Schwartz Ph.D.Chief Executive Officer and President
Galena Biopharma, Inc.
$490.0K
Mark J. Murray Ph.D.Chief Executive Officer, President and Director
Tekmira Pharmaceuticals Corporation
$377.5K
Kleanthis G. Xanthopoulos Ph.D.Chief Executive Officer, President, Principal Financial & Accounting Officer and Director
Regulus Therapeutics Inc.
$600.0K
Compensation as of Fiscal Year 2013.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ALNYLAM PHARMACEUTICALS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.